Oxytocin may be useful to increase trust in others and decrease disruptive behaviours in patients with Prader-Willi syndrome: a randomised placebo-controlled trial in 24 patients
| Autor: | Catherine Arnaud, Geneviève Demeer, Virginie Ehlinger, Virginie Laurier, Denise Thuilleaux, Maithé Tauber, Joseba Jauregui, Catherine Molinas, Carine Mantoulan, Bernadette Rogé, Gwenaelle Diene, Pierre Copet |
|---|---|
| Přispěvatelé: | BMC, Ed., Centre de Référence du Syndrome de Prader-Willi, Pôle Enfants [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre de Physiopathologie Toulouse Purpan (CPTP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hôpital Marin d'Hendaye, Octogone Unité de Recherche Interdisciplinaire (Octogone), Université Toulouse - Jean Jaurès (UT2J), Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps (LEASP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Toulouse [Toulouse] |
| Jazyk: | angličtina |
| Rok vydání: | 2011 |
| Předmět: |
Male
Pediatrics Placebo-controlled study lcsh:Medicine [SDV.GEN] Life Sciences [q-bio]/Genetics Oxytocin law.invention Placebos 0302 clinical medicine Randomized controlled trial law Medicine Genetics(clinical) Pharmacology (medical) MESH: Double-Blind Method Young adult Genetics (clinical) Medicine(all) 0303 health sciences Cognition General Medicine MESH: Young Adult Female Prader-Willi Syndrome medicine.drug Adult medicine.medical_specialty Adolescent MESH: Placebos Placebo Young Adult 03 medical and health sciences Double-Blind Method Social skills MESH: Oxytocin Humans 030304 developmental biology MESH: Adolescent [SDV.GEN]Life Sciences [q-bio]/Genetics MESH: Humans business.industry Research lcsh:R MESH: Adult MESH: Male MESH: Prader-Willi Syndrome Nasal administration business MESH: Female 030217 neurology & neurosurgery |
| Zdroj: | Orphanet Journal of Rare Diseases Orphanet Journal of Rare Diseases, 2011, 6 (1), pp.47. ⟨10.1186/1750-1172-6-47⟩ Orphanet Journal of Rare Diseases, Vol 6, Iss 1, p 47 (2011) Orphanet Journal of Rare Diseases, BioMed Central, 2011, 6 (1), pp.47. ⟨10.1186/1750-1172-6-47⟩ |
| ISSN: | 1750-1172 |
| DOI: | 10.1186/1750-1172-6-47⟩ |
| Popis: | Background Prader-Willi syndrome (PWS) is a complex neurodevelopmental genetic disorder with hypothalamic dysfunction, early morbid obesity with hyperphagia, and specific psychiatric phenotypes including cognitive and behavioural problems, particularly disruptive behaviours and frequent temper outbursts that preclude socialization. A deficit in oxytocin (OT)-producing neurons of the hypothalamic paraventricular nucleus has been reported in these patients. Methods In a double-blind, randomised, placebo-controlled study, 24 adult patients with PWS received a single intranasal administration of 24 IU of OT or placebo and were tested 45 min later on social skills. Behaviours were carefully monitored and scored using an in-house grid as follows: over the two days before drug administration, on the half-day following administration, and over the subsequent two days. All patients were in a dedicated PWS centre with more than ten years of experience. Patients are regularly admitted to this controlled environment. Results Patients with PWS who received a single intranasal administration of OT displayed significantly increased trust in others (P = 0.02) and decreased sadness tendencies (P = 0.02) with less disruptive behaviour (P = 0.03) in the two days following administration than did patients who received placebo. In the half-day following administration, we observed a trend towards less conflict with others (p = 0.07) in the OT group compared with the placebo group. Scores in tests assessing social skills were not significantly different between the two groups. Conclusions This study needs to be reproduced and adapted. It nevertheless opens new perspectives for patients with PWS and perhaps other syndromes with behavioural disturbances and obesity. Trial registration number ClinicalTrials.gov: NCT01038570 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink